Abstract
The pharmacokinetics of the hypoxic radio-sensitizer nimorazole were studied in 19 individuals after single oral doses of between 0.5-3.5 g. HPLC measurements showed, after a rapid absorption, a linear relationship between peak plasma concentration and given dose. Mean elimination half life was 3.1 h. A tendency to a dose-dependent variation in the apparent volume of distribution, total body clearance and elimination half life suggest non-linear pharmacokinetics of nimorazole. Tumour concentrations measured in 5 patients gave tumour/plasma ratios between 0.8-1.3. No toxicity was observed. The results indicate that nimorazole may have potential as a clinically useful hypoxic radiosensitizer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Rights and permissions
About this article
Cite this article
Overgaard, J., Overgaard, M. & Timothy, A. Studies of the pharmacokinetic properties of nimorazole. Br J Cancer 48, 27–34 (1983). https://doi.org/10.1038/bjc.1983.153
Issue Date:
DOI: https://doi.org/10.1038/bjc.1983.153
This article is cited by
-
The anti-malarial atovaquone increases radiosensitivity by alleviating tumour hypoxia
Nature Communications (2016)
-
Misonidazole neuropathy A prospective study
Journal of Neuro-Oncology (1988)
